Lee Health greenlights full commercial rollout of HeraMED’s maternity program
Lee Health, a approximately US$3 billion non-profit health system in Southwest Florida delivering more than 8,000 babies annually, has approved the full commercial deployment of HeraMED’s HeraCARE platform, formally launching its “Digital Pregnancy Journey Program” on 15 September 2026. The decision follows the successful completion of a six-month pilot and marks HeraMED’s transition from pilot partner to commercial partner in the US. The initial Statement of Work (SOW) is valued at US$317,200, with a recurring SaaS model now in place to support staged scale-up.
HeraMED Limited (ASX: HMD) is a medical data and technology company focused on the digital transformation of women’s and maternity care.
When big ASX news breaks, our subscribers know first
From pilot to commercial partner — what the numbers showed
Lee Health’s approval was grounded in the outcomes from its six-month evaluation, with the data supporting a clear case for full deployment. The pilot validated the model against clinical, patient experience, and operational criteria before any scale-up was approved.
The Phase 1 pilot results covered 44 patients and also quantified operational gains beyond adoption rates, with the digital pathway estimated to free roughly 32 additional prenatal slots and cut approximately 74 miles of patient travel per pregnancy.
Key pilot KPIs included:
- 92% virtual adoption rate
- 100% likelihood to recommend
- Program Net Promoter Score (NPS) of 60
- Remote patient monitoring (RPM) device NPS of 75
- An 11-visit digital-first prenatal pathway, compared with approximately 15 in-person visits under the traditional model
Anoushka Gungadin, Managing Director & CEO, HeraMED
“This is the moment we have been building toward — moving from a successful phase 1 to full-scale commercial deployment inside a health system of Lee Health’s calibre as a new model of maternity care…”
What the commercial deal looks like
The initial SOW covers the onboarding of the next 200 pregnant women and is structured as follows:
| Component | Detail | Notes |
|---|---|---|
| HeraCARE SaaS licences | 200 licences, 12-month term | Per-mother recurring licence model |
| Maternity monitoring kits | 200 kits comprising FDA-cleared HeraBEAT fetal heart rate monitor and connected blood pressure cuff | At-home RPM devices |
| Customised care plans | 4 plans: low-risk prenatal care, hypertension in pregnancy, postpartum care, and patient engagement | Scope to expand into additional women’s health pathways |
| Implementation, integration & support | Epic integration fee, implementation fees, logistics, device and application support | Embedded within Lee Health’s existing EMR environment |
| Total initial SOW value | US$317,200 | Contracted revenue, in line with HeraMED’s pricing guidance |
Once the initial 200 licences are exhausted, additional activated licences and monitoring device kits can be ordered in mutually agreed increments of 20, 50, 100 or larger cohorts, each subject to additional fees. This incremental ordering mechanism is where the recurring revenue potential compounds as Lee Health’s clinic onboarding scales.
Dr Cherrie Morris, Chief Physician Executive and Vice President, Women’s Services, Lee Health
“…By integrating technology with traditional care, we can meet patients where they are while maintaining access to the services and support they need.”
Why Epic integration matters
Epic is the dominant electronic medical record (EMR) platform used across US health systems, meaning clinical teams already conduct their daily workflows within it. HeraCARE’s integration into Lee Health’s Epic environment is commercially significant because it removes a key adoption barrier, allowing clinicians to monitor patients without switching between systems, reducing administrative load in the process.
The bigger picture for HeraMED’s US strategy
The Lee Health deployment provides HeraMED with a reference partner in the world’s largest healthcare market. HeraMED is applying the same commercial framework to its wider US pipeline, targeting health systems that meet five criteria:
The commercial framework now being applied across HeraMED’s US pipeline was funded by a US expansion capital raise of $3.2 million completed earlier in 2026, structured specifically to move the company from pilot partnerships into revenue-generating deployments across the US, Australia, and Europe.
- Dedicated maternity and women’s health service
- Seeking to improve maternal-fetal care outcomes
- Connected hybrid/virtual care strategic plans
- EMR integration and technology capability
- Exposure to regional obstetric supply constraints
The announcement also references two pipeline contexts, though neither represents a confirmed deal. Strategic channel partner Philips and opportunities associated with the US$50 billion Rural Health Transformation Program are both named as relevant to HeraMED’s broader US pipeline.
For investors, the Lee Health SOW establishes a validated SaaS pricing model with a recognisable health system, one with approximately 2,000 active pregnancies at any given time. The incremental ordering structure creates a repeatable commercial template that, if replicated across additional health systems, would underpin the scaling of contracted recurring revenue in the US market.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Over 20,000 subscribers rely on it to stay ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.